CAR-T细胞治疗肿瘤领域研究进展  

Research Progress in the Field of CAR-T Cell Therapy for Tumor Treatment

作　　者：彭正康 黄育婷 任瑞 钟渚永 段齐阳 潘家宇 邱黄珺 袁纹秀 李谦[1] PENG Zhengkang;HUANG Yuting;REN Rui;ZHONG Zhuyong;DUAN Qiyang;PAN Jiayu;QIUHuangjun;YUAN Wenxiu;LI Qian(School of Life Science and Technology,China Pharmaceutical University,Nanjing 211198,China)

机构地区：[1]中国药科大学生命科学与技术学院,江苏南京211198

出　　处：《药物生物技术》2024年第3期325-330,共6页Pharmaceutical Biotechnology

摘　　要：近年来嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)技术在肿瘤治疗领域取得了巨大的成功,其通过体外对T细胞进行修饰转基因扩增后输入人体,经过特异性识别对肿瘤细胞进行杀伤。虽然CAR-T细胞治疗在血液瘤中取得显著的疗效,但在实体瘤中疗效欠佳,文章主要整理近年来国内外学者在CAR-T细胞治疗领域的最新进展,包括在血液瘤、实体瘤以及CAR-T联用新技术方面,对其为提高CAR-T治疗效果所做的工作进行综述。In recent years,chimeric antigen receptor T-cell(CAR-T)therapy has achieved significant success in the field of oncology.This treatment involves genetically modifying T cells ex vivo to express a chimeric antigen receptor,which allows for the targeted expansion and subsequent infusion into the patient's body to specifically recognize and eliminate tumor cells.Although CAR-T therapy has demonstrated remarkable efficacy in hematological malignancies,its effectiveness in solid tumors has been less satisfactory.This article primarily consolidates the latest advancements in CAR-T cell therapy,both domestically and internationally,including developments in the treatment of hematological and solid tumors,as well as the integration of new technologies with CAR-T therapy.It provides an overview of the work conducted to enhance the therapeutic outcomes of CAR-T treatments.

关 键 词：嵌合抗原受体T细胞 血液瘤 实体瘤 联合治疗 抗体药物 生物纳米材料 溶瘤病毒 

分 类 号：R730.5[医药卫生—肿瘤]